Product Description
Mechanisms of Action: NEU Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Colombia, Italy, Netherlands, Poland, Spain, United Kingdom
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Arthralgia|Influenza, Human
Phase 1: Dengue
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 200925 | P2 |
Unknown Status |
Influenza, Human |
2026-12-09 |
|
| NCT04494412 | P2 |
Recruiting |
Arthralgia|Influenza, Human |
2026-12-09 |
25% |
| ZAP-DENGUE | P1 |
Recruiting |
Dengue |
2025-09-30 |
|
| Zanamivir, Ph 2a, Infant/Neonate complicated Influenza Patients,5-10 Day IV RD, PK/Safety Study | P2 |
Active, not recruiting |
Influenza, Human |
2023-11-29 |